MELBOURNE, AUSTRALIA 24 July 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, today releases its Appendix 4C for the fourth quarter of FY 2023.
During the quarter, Arovella continued to advance its iNKT cell therapy towards first-in-human clinical trials. Arovella’s technology provides key advantages over existing CAR-T cell therapies and has the potential to be applied to both blood cancers and solid tumours.
For more information, download the attached PDF.
Download this document
